The National Institutes of Health awarded Joslin Diabetes Center $24.3 million to fund a clinical trial to study a potential treatment for kidney disease in people with type 1 diabetes.

The five-year trial will evaluate the possible benefits of allopurinol, an FDA approved uric acid lowering drug, in reducing kidney function loss among people with type 1 diabetes. The study stems from findings from Joslin and other investigators linking higher levels of serum uric acid to the risk of kidney complications in diabetes.

Click here to read the full article.